Phase 2 enzyme inducer sulphoraphane blocks prostaglandin and nitric oxide synthesis in human articular chondrocytes and inhibits cartilage matrix degradation

Rheumatology (United Kingdom)

Volumn 51, Issue 6, 2012, Pages 1006-1016

  Kim, Hyun Ah ^a   Yeo, Yunshin ^a   Jung, Hyun A ^a   Jung, Young O ^b   Park, Su J ^a   Kim, Song J ^c  

^a Hallym University   (South Korea)

^b Kangnam Sacred Heart Hospital   (South Korea)

^c Kongju National University   (South Korea)

Author keywords

Chondrocyte; Nitric oxide; Osteoarthritis; PGE 2; Sulphoraphane

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; CYCLOOXYGENASE 2; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LUCIFERASE; MESSENGER RNA; NITRIC OXIDE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2; PROTEOGLYCAN; SULFORAPHANE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE MATRIX; CELL STIMULATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EXPLANT; HUMAN; HUMAN CELL; INHIBITION KINETICS; KNEE OSTEOARTHRITIS; MICROSOME; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AGED; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; COLLAGEN TYPE II; CYCLOOXYGENASE 2; DINOPROSTONE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTERLEUKIN-1BETA; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MIDDLE AGED; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRILES; OSTEOARTHRITIS, KNEE; SULFOXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861469207     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker525     Document Type: Article

References (30)

1. Chen XL, Varner SE, Rao AS et al. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. J Biol Chem 2003;278:703-11.
2. Zhang Y, Kensler TW, Cho CG et al. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 1994; 91:3147-50.
3. Brooks JD, Paton VG, Vidanes G et al. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev 2001;10:949-54.
4. Dinkova-Kostova AT, Liby KT, Stephenson KK et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005;102: 4584-9.
5. Kim HA, Yeo Y, Kim WU et al. Phase 2 enzyme inducer sulphoraphane blocks matrix metalloproteinase production in articular chondrocytes. Rheumatology 2009;48: 932-8.
6. Appleton CT, Pitelka V, Henry J et al. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum 2007;56:1854-68.
7. Amin AR, Attur M, Patel RN et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritisaffected cartilage. Influence of nitric oxide. J Clin Invest 1997;99:1231-7.
8. Masuko-Hongo K, Berenbaum F, Humbert L et al. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum 2004;50: 2829-38.
9. Attur M, Al-Mussawir HE, Patel J et al. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor. J Immunol 2008; 181:5082-8.
10. Loeser RF, Carlson CS, Del Carlo M et al. Detection of nitrotyrosine in aging and osteoarthritic cartilage: correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 2002;46: 2349-57.
11. Abramson SB. Osteoarthritis and nitric oxide. Osteoarthritis Cartilage 2008;16:S15-20.
12. Del Carlo M Jr, Loeser RF. Nitric oxide-mediated chondrocyte cell death requires the generation of additional reactive oxygen species. Arthritis Rheum 2002;46: 394-403.
13. Pelletier JP, Lascau-Coman V, Jovanovic D et al. Selective inhibition of inducible nitric oxide synthase in experimental osteo-arthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999;26:2002-14.
14. Nam J, Aguda BD, Rath B et al. Biomechanical thresholds regulate inflammation through the NF-kappaB pathway: experiments and modeling. PLoS One 2009;4:e5262.
15. Kim HA, Cho ML, Choi HY et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006;54:2152-63.
16. Kim HA, Lee KB, Bae SC. The mechanism of low-concentration sodium nitroprusside-mediated protection of chondrocyte death. Arthritis Res Ther 2005;7: R526-35.
17. Ritz SA, Wan J, Diaz-Sanchez D. Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract. Am J Physiol Lung Cell Mol Physiol 2007;292:L33-9.
18. Wu L, Noyan Ashraf MH, Facci M et al. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci USA 2004;101:7094-9.
19. Talalay P, Fahey JW, Healy ZR et al. Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc Natl Acad Sci USA 2007;104: 17500-5.
20. Zhao X, Song S, Sun G et al. Neuroprotective role of haptoglobin after intracerebral hemorrhage. J Neurosci 2009;29:15819-27.
21. Healy ZR, Lee NH, Gao X et al. Divergent responses of chondrocytes and endothelial cells to shear stress: cross-talk among COX-2, the phase 2 response, and apoptosis. Proc Natl Acad Sci USA 2005;102:14010-5.
22. Kong JS, Yoo SA, Kim HS et al. Inhibition of synovial hyperplasia, rheumatoid T cell activation, and experimental arthritis in mice by sulforaphane, a naturally occurring isothiocyanate. Arthritis Rheum 2010;62: 159-70.
23. Facchini A, Stanic I, Cetrullo S et al. Sulforaphane protects human chondrocytes against cell death induced by various stimuli. J Cell Physiol 2011;226:1771-9.
24. Hu R, Hebbar V, Kim BR et al. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther 2004;310:263-71.
25. Ye AT, Dinkova-Kostova AL, Wade KL et al. Quantitative determination of dithiocarbamates in human plasma, serum erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta 2002;316:43-53.
26. Shapiro TA, Fahey JW, Wade KL et al. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol Biomarkers Prev 2001;10:501-8.
27. Heiss E, Herhaus C, Klimo K et al. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001;276: 32008-15.
28. Karmakar S, Weinberg MS, Banik NL et al. Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience 2006;141:1265-80.
29. Cheung KL, Kong AN. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 2010;12:87-97.
30. Heiss E, Gerhäuser C. Time-dependent modulation of thioredoxin reductase activity might contribute to sulforaphane-mediated inhibition of NF-kappaB binding to DNA. Antioxid Redox Signal 2005;7:1601-11.